Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/1926| Title: | Antibiotics for neonatal sepsis in low-income and middle-income countries—where to go from here? | Authors: | Schlapbach, L. J. Carrol, E. D. van Rossum, A. |
Issue Date: | 2021 | Source: | 21, (12), 2021, p. 1617-1618 | Pages: | 1617-1618 | Journal: | The Lancet Infectious Diseases | Abstract: | L20157152152021-11-30 | DOI: | 10.1016/S1473-3099(21)00199-7 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2015715215&from=exporthttp://dx.doi.org/10.1016/S1473-3099(21)00199-7 | | Keywords: | antibiotic therapy;high risk population;hospital;gentamicin;clavulanic acid;ceftazidime;ampicillin;human;Klebsiella;meropenem;middle income country;newborn sepsis;note;whole genome sequencing;amikacinamoxicillin;lowest income group;piperacillin;tazobactam;antibiotic resistance | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.